Bleomycin toxicity

From RadsWiki

Jump to: navigation, search

Contents

[edit] Discussion of Bleomycin toxicity

  • Bleomycin is commonly used, either alone or in combination with other chemotherapeutic agents, in the treatment of squamous cell carcinomas (of the head and neck, cervix, and vagina), testicular carcinomas, and Hodgkin lymphoma.
  • Bleomycin-induced lung injury usually occurs in 3%–5% of treated patients, although there is a marked increased risk if the total cumulative dose is more than 450 units.
  • The risk of developing lung injury is increased in the elderly and in patients receiving oxygen therapy, with a history of prior thoracic irradiation, or in whom therapy is reinstituted within 6 months of discontinuation.
  • The prognosis is poor, with most patients dying of respiratory failure within 3 months of onset of symptoms.

[edit] Imaging Findings for Bleomycin toxicity

[edit] Images

Patient #1

[edit] See Also

[edit] External Links

Goldminer: Bleomycin toxicity

[edit] References for Bleomycin toxicity